AKT1 and osteosarcoma: Chen et al developed a nanoparticle, TGIC-CA (TC), and found that combining TC/miR-22 with volasertib synergistically inhibited the PI3K (phosphoinositide 3-kinase)/Akt (protein kinase B) signaling pathway for anti-osteosarcoma effects.187